A meta-analysis of margin size and local recurrence in oral squamous cell carcinoma

被引:113
作者
Anderson, Caroline Rachael [1 ]
Sisson, Katherine [2 ,3 ]
Moncrieff, Marc [1 ,4 ,5 ]
机构
[1] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England
[2] Norfolk Univ Hosp, Dept Histopathol, Norwich NR4 7UY, Norfolk, England
[3] Norwich Univ Hosp, Dept Histopathol, Norwich NR4 7UY, Norfolk, England
[4] Norfolk Univ Hosp, Dept Plast & Reconstruct Surg, Norwich NR4 7UY, Norfolk, England
[5] Norwich Univ Hosp, Dept Plast & Reconstruct Surg, Norwich NR4 7UY, Norfolk, England
关键词
Oral squamous cell carcinoma; Excision margins; Pathology; SURGICAL MARGINS; POSTOPERATIVE RADIOTHERAPY; BUCCAL MUCOSA; CANCER; HEAD; RESECTION; SURGERY; MOUTH; FLOOR; RISK;
D O I
10.1016/j.oraloncology.2015.01.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Excision margins for oral squamous cell carcinoma (OSCC) are poorly understood. Close (<5 mm) and involved (<1 mm) pathological margins are key indicators of the need for adjuvant treatment. This review aimed to assess the impact of pathological margin size on local recurrence rates. Methods: MEDLINE and EMBASE were searched for studies that looked at local recurrence following excision of primary OSCC without adjuvant therapy. Five studies met the inclusion criteria. Results: Recurrence rates were pooled to give a 21% absolute risk reduction (95% confidence interval 12-30%, p =< 0.00001) in local recurrence with margins clear by more than 5 mm. Unweighted pooled recurrence rates were 20% in patients with margins clear by more than 5 mm. Conclusion: These findings suggest that a 5 mm pathological margin is the minimum acceptable margin size in OSCC. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:464 / 469
页数:6
相关论文
共 46 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]  
[Anonymous], COCHRANE DATABASE SY
[3]  
[Anonymous], 2002, MCGRAW HILL CONCISE
[4]  
[Anonymous], 2011, STANDARDS DATASETS R
[5]  
[Anonymous], COCHRANE DATABASE SY
[6]  
[Anonymous], HEAD NECK
[7]  
[Anonymous], HEAD NECK CANC TREAT
[8]  
[Anonymous], COCHRANE HDB SYSTEMA
[9]  
[Anonymous], RES PROJ COCHR RISK
[10]  
[Anonymous], EUR ARCH OTORHINOLAR